Edition:
United Kingdom

Cerecor Inc (CERC.OQ)

CERC.OQ on NASDAQ Stock Exchange Capital Market

1.94USD
15 Dec 2017
Change (% chg)

$0.03 (+1.57%)
Prev Close
$1.91
Open
$1.92
Day's High
$1.99
Day's Low
$1.88
Volume
49,087
Avg. Vol
90,525
52-wk High
$2.63
52-wk Low
$0.34

Summary

Name Age Since Current Position

Uli Hacksell

67 2017 Chairman of the Board

Robert Moscato

42 2017 President, Chief Operating Officer, Director

Isaac Blech

67 2012 Vice Chairman of the Board

Mariam Morris

48 2017 Chief Financial Officer

Bernadine Fraser

46 2012 Vice President, Clinical Operations and Project Management

M. James Barrett

74 2014 Director

Steven Boyd

2017 Director

Peter Greenleaf

47 2017 Director

Phil Gutry

41 2015 Director

Randal Jones

2017 Director

Magnus Persson

57 2012 Director

Mayukh Sukhatme

39 2014 Director

Frank Torti

2014 Director

Biographies

Name Description

Uli Hacksell

Dr. Uli Hacksell, Ph.D. serves as Chairman of the Board of the Company. Dr. Hacksell has served as the Chairman of the Board since May 2015. From September 2000 to March 2015, Dr. Hacksell served as the Chief Executive Officer and as a director of ACADIA Pharmaceuticals Inc. He previously served as the Executive Vice President of Drug Discovery of ACADIA and held various senior executive positions at Astra AB, a pharmaceutical company, including Vice President of Drug Discovery and Technology and President of Astra Draco AB, one of the company’s largest research and development subsidiaries, where he directed an organization of more than 1,100 employees. He also served as Vice President of CNS Preclinical R&D at Astra Arcus, another Astra subsidiary. Earlier in his career, Dr. Hacksell held the positions of Professor of Organic Chemistry and Department Chairman at Uppsala University in Sweden and also served as Chairman and Vice Chairman of the European Federation of Medicinal Chemistry. Dr. Hacksell received his Master of Pharmacy and a Ph.D. in Medicinal Chemistry from Uppsala University.

Robert Moscato

Mr. Robert C. Moscato, Jr., serves as President, Chief Operating Officer, Director of the Company. Mr. Moscato has a breadth of healthcare and pharmaceutical industry experience. In June 2011, he co-founded and has since been the Chief Executive Officer of Zylera Pharmaceuticals, LLC, a pediatric focused specialty pharmaceutical company. From February 2006 until May 2011, Mr. Moscato served as the Chief Operating Officer of Deston Therapeutics, LLC, which was a specialty pharmaceutical company concentrating on acute care therapies. Prior to that he held various positions in sales, sales management, business analysis and product marketing. Mr. Moscato has extensive experience with product launches, sales force development and channel marketing. He holds an AS degree in Food Science and Nutrition from SUNY Farmingdale, BS degree in Healthcare Management from St. Francis College and an MBA with a concentration in Marketing from IONA College.

Isaac Blech

Mr. Isaac Blech is the Vice Chairman of the comany since March 2012. Mr. Blech currently serves on a variety of boards of directors. He has served on the board of ContraFect Corporation, a biotechnology company, since August 2011 and Medgenics since May 2011. He has served as Vice Chairman of Edge Therapeutics, Inc. since January 2013, Centrexion Corp, a biotechnology company, since February 2013 and RestorGenex since November 2013. He has also served on the board of The SpendSmart Payments Company, or SpendSmart, an online and retail payment company, since March 2011 and as Vice Chairman since November 2011. He has served on the board of Premier Alliance Group, Inc., or Premier Alliance, an advisory, consulting and resource service company, since June 2011 and as Vice Chairman since May 2012. Prior to joining our board of directors, He played a role in establishing some of the leading biotechnology companies including Celgene, ICOS Corporation, Pathogenesis Corporation, Nova Pharmaceutical Corporation and Genetic Systems Corporation. Mr. Blech received his B.A. in Medicine from Baruch College.

Mariam Morris

Ms. Mariam E. Morris is Chief Financial Officer of the company. Ms. Morris is the sole proprietor of Mariam Morris CPA, a full service tax, accounting and business consulting firm, which she founded in January 2009. Prior to that, Ms. Morris was the Chief Financial Officer of Sucampo Pharmaceuticals, Inc., from February 2004 to July 2009. From 1991 until 2001, Ms. Morris was an auditor for PricewaterhouseCoopers. She received her B.B.A. in Accounting from Texas Tech University and her M.S. in Taxation from Old Dominion University. Ms. Morris is a Certified Public Accountant in the state of Texas.

Bernadine Fraser

Dr. Bernadine Heather Fraser, Ph.D is the Vice President, Clinical Operations and Project Management of the company. Prior to joining our company, Dr. Fraser served as the Senior Director of Preclinical and Clinical Sciences at Anthera Pharmaceuticals Inc., a biopharmaceutical company, from October 2006 through March 2012. She served in a variety of roles at CV Therapeutics, Inc., a biopharmaceutical company, which was acquired by Gilead Sciences, Inc. in 2009, from June 2000 through October 2006. Dr. Fraser received her B.S. in Zoology from the University of British Columbia, her M.S. in Pharmaceutical Sciences from the University of Montana and her Ph.D. in Pharmacology from the University of Alberta. She has also completed a post-doctoral fellowship at the Johns Hopkins University School of Medicine.

M. James Barrett

Dr. M. James Barrett is the Director of the company since July 2014. Dr. Barrett currently serves as a General Partner of New Enterprise Associates, Inc., or NEA, a venture capital firm, since 2001 where he specializes in biotechnology companies. In 1997, Dr. Barrett founded Sensors for Medicine and Science, Inc., now called Senseonics, Incorporated, or Senseonics, a medical device company, and served as its Chairman and Chief Executive Officer until he joined NEA in 2001. Prior to 1997, He served as the Chief Executive Officer of three different NEA-funded companies, including Genetic Therapy, Inc., Life Technologies, Inc. and Bethesda Research Labs. Dr. Barrett currently serves on the board of directors of Clovis Oncology, Inc., GlycoMimetics, Inc., Loxo Oncology, Inc., Roka Bioscience, Inc., Supernus Pharmaceuticals, Inc. and Zosano Pharma, Inc. and numerous privately held companies. He formerly served on the board of directors of CoGenesys Inc., which was acquired by Teva Pharmaceutical Industries in 2008, Iomai Corporation, which was acquired by Intercell AG in 2008, MedImmune, Inc., which was acquired by AstraZeneca plc in 2007, Pharmion Corp., which was acquired by Celgene in 2007, Inhibitex, Inc., which was acquired by Bristol-Myers Squibb Company, or Bristol-Myers, in 2012, Targacept, Inc. and Peptimmune, Inc. Dr. Barrett received his B.S. in Chemistry from Boston College, his Ph.D in Biochemistry from the University of Tennessee and his M.B.A. from the University of Santa Clara.

Steven Boyd

Mr. Steven Boyd is Director of the company. He is the Chief Investment Officer of Armistice Capital. He founded Armistice in 2012, which was named "best new hedge fund" by Hedge Funds Review the following year. Prior to Armistice, Mr. Boyd had been an analyst at Senator Investment Group and York Capital. He started his career at McKinsey & Company.

Peter Greenleaf

Mr. Peter S. Greenleaf is Director of the company. He is currently serves as Chief Executive Officer and is a member of the board of directors of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) , positions he has held since March 2014. Prior to joining Sucampo, from June 2013 to March 2014, Mr. Greenleaf served as Chief Executive Officer and a member of the board of directors of Histogenics Corporation, a regenerative medicine company. Prior to joining Histogenics, from 2006 to 2013, Mr. Greenleaf was employed by MedImmune LLC, the global biologics arm of AstraZeneca, where he most recently served as President. From January 2010 to June 2013, Mr. Greenleaf also served as President of MedImmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group. He is also a member of the board of directors of the Biotechnology Industry Organization (BIO), where he serves on the Governing Boards of the Emerging Companies and Health Sections.

Phil Gutry

Mr. Phil Gutry is the Director of the company since April 2015. Since May, 2011, Mr. Gutry has served as a Principal of MPM Capital, Inc., or MPM, a venture capital firm with a focus on the life sciences industry. Prior to joining MPM, Mr. Gutry worked in the Corporate Development Group at Gilead Sciences, Inc., a research-based biopharmaceutical company, for approximately five years. Mr. Gutry previously worked at Riverside Partners, LLC, a healthcare focused private equity investment firm, and at The Wilkerson Group. Mr. Gutry currently serves on the board of directors of Potenza Therapeutics, Inc. and Amphivena Therapeutics, Inc. He received his A.B. in Earth Sciences from Dartmouth College and an M.B.A. in Healthcare Management from The Wharton School.

Randal Jones

Mr. Randal O. Jones serves as Director of the Company. Since January 2006, Mr. Jones has served as the President of Fremantle Corporation, a management and consulting service and has been the manager and Chief Financial Officer of Zylera Pharmaceuticals, LLC and its subsidiaries, a pediatric focused specialty pharmaceutical company. He has been a manager and the Chief Executive Officer of TRx Pharmaceuticals, LLC since December 2005. Mr. Jones is a former CPA and holds a BS in Finance from Arizona State University, as well as an MBA with an emphasis in Managerial Accounting from the University of Denver.

Magnus Persson

Dr. Magnus Persson, M.D., Ph.D. is the Director of the company since August 2012. Since September 2013, Dr. Persson has served as a Director at Scandinavian Node InnoLIFE at the Karolinksa Institutet in Stockholm, Sweden, where he has also served as an Associate Professor in Physiology since September 1994. Dr. Persson has served as a practicing pediatrician at CityAkuten in Stockholm, Sweden since December 2012. He is also currently the Chief Executive Officer of C10Pharma AS in Oslo, Norway, a preclinical-stage pharmaceutical company, a position he has held since December 2012. Prior to joining our board of directors, Dr. Persson served as a Partner at HealthCap, a Swedish-based venture capital firm, from January 2008 through December 2009, and as a Managing Partner at The Column Group, a San Francisco-based venture capital firm, from January 2010 through November 2011. From November 2011 until September 2013, Dr. Persson was a Physician at Stockholms Läns Landsting in Stockholm, Sweden. He founded Aerocrine AB, a medical technology company in 1994. He has also served on the boards of Contera AS, a biotechnology company, since December 2011, Karolinska Institutet Innovations AB, a technology transfer company, since December 2011, Galecto AB, a biotechnology company, since January 2013, AscendxSpine Inc., a medical device company, since December 2012, BioWorks AB, a laboratory equipment company, since July 2013 and SLS Ventures AB, a life science venture capital firm since March 2012. He received his M.D. and Ph.D. in physiology from Karolinska Institutet.

Mayukh Sukhatme

Dr. Mayukh Sukhatme, M.D. is the Director of the company since July 2014. Dr. Sukhatme currently serves as a Partner of Apple Tree Partners IV, L.P., a position he has held since December 2013. Prior to joining Apple Tree Partners, Dr. Sukhatme served as Managing Director for Global Healthcare at Hutchin Hill Capital, a multistrategy fund based in New York from September 2010 to December 2013. He served as Portfolio Manager for Sio Capital from July 2009 to September 2010. Dr. Sukhatme received his M.D. from Harvard Medical School and his B.S. in Biology and Literature from Massachusetts Institute of Technology.

Frank Torti

Dr. Frank Torti is the Director of the company since July 2014. Mr. Torti currently serves as a Partner of NEA. Prior to joining NEA in 2007, Dr. Torti worked for the Duke University Center for Clinical & Genetic Economics, where he was involved in clinical trials research and economic evaluations of multinational clinical trials. Dr. Torti's experience also includes public market investing at Wasatch Advisors and business development work with the consumer-directed healthcare startup Revolution Health Group LLC. He is currently a member of the board of directors of Galera Therapeutics Inc. and Neotract Inc. Mr. Torti received his M.D. from the University of North Carolina School of Medicine, his M.B.A. from Harvard Business School, and his B.A. from the University of North Carolina.